PD-1 and PD-L1 Inhibitors Market
PD-1 and PD-L1 Inhibitors Market Scope: Industry
Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
PD-1 and PD-L1 Inhibitors Market Size and Growth
The PD-1 and PD-L1 inhibitors market is experiencing robust growth due to increasing cancer prevalence and advancements in immunotherapy. In 2023, the market size is estimated at $25 billion, with a projected CAGR of 15% through 2030, driven by rising investment in research and a growing number of approved therapies. Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Merck
◍ Novartis
◍ Bristol-Myers Squibb
◍ GlaxoSmithKline
◍ Regeneron Pharmaceuticals
◍ Eli Lilly and Company
◍ Roche Genetech
◍ AstraZeneca
◍ Jiangsu HengRui Medicine Co., Ltd.
◍ Curis Inc.
◍ Aurigene
The PD-1 and PD-L1 inhibitors market is competitive, with Merck (Keytruda) and Bristol-Myers Squibb (Opdivo) as leaders. Companies like Novartis, Roche, and AstraZeneca invest in innovation and clinical trials, while Regeneron and Eli Lilly expand indications, driving market growth. Sales figures reflect their success in oncology treatments.
Request Sample Report
